8 meta-analysis results to guide diabetes drug choice
Study clarifies the effects of SGLT2 inhibitors and GLP1 agonists on cardiovascular and renal outcomes

A meta-analysis has compared SGLT2 inhibitors and GLP1 receptor agonists for their effects on cardiovascular and renal outcomes in people with type 2 diabetes.
Each drug class has been shown to improve cardiovascular and renal outcomes.